There is a need for newer therapeutic agents that improve the safety of allergen immunotherapy, provide ease of delivery to patients that fosters compliance and allows access to a greater proportion of the allergic population who could benefit from this disease-modifying treatment, and achieve an acceptable therapeutic benefit for patients committing to the treatment. The advances in sublingual allergen immunotherapy are encouraging, as this offers patients a noninjectable form of treatment of inhalant allergies. The continued research and development of the novel therapeutic constructs discussed in this article holds the promise of accomplishing the aforementioned goals in the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.iac.2015.08.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Allergic rhinitis.
Allergy Asthma Clin Immunol
December 2024
Division of Allergy & Immunology, Department of Medicine, Queen's University, Kingston, ON, Canada.
Allergic rhinitis (AR) is a common disorder that is strongly linked to asthma and conjunctivitis. Classic symptoms include nasal congestion, nasal itch, rhinorrhea and sneezing. A thorough history, physical examination and assessment of allergen sensitization are important for establishing the diagnosis of AR.
View Article and Find Full Text PDFTwo-year follow-up after drug desensitization in mucopolysaccharidosis.
Orphanet J Rare Dis
December 2024
Post Graduate School in Allergology and Internal Medicine "Guido Baccelli", Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, Aldo Moro University of Bari, Bari, 70124, Italy.
Background: Mucopolysaccharidosis (MPS) type 1 S and type 2 are rare lysosomal storage disorders characterized by impaired enzyme production, resulting in glycosaminoglycans accumulation within lysosomes. Enzyme Replacement Therapy (ERT) with laronidase and idursulfase are first line treatments, respectively. However, infusion-related hypersensitivity reactions (HR) may lead to ERT discontinuation.
View Article and Find Full Text PDFShrimp allergen extract immunotherapy induces prolonged immune tolerance in a gastro-food allergy mouse model.
PLoS One
December 2024
Department of Pharmacy Practice, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
Food allergies are a global health problem that continues to grow annually, with a prevalence of more than 10%. Shrimp allergy is the most common and life-threatening allergy. There is no cure for food allergies, but shrimp allergen extract (SAE) offers promise as a treatment through allergen-specific immunotherapy (AIT).
View Article and Find Full Text PDFBackground: Remission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high-quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut-specific IgE (sIgE) levels which is closely correlated with age.
View Article and Find Full Text PDFA Model for Consolidating High-Risk Allergy Procedures in Clinic.
Ochsner J
January 2024
Department of Allergy and Immunology, Ochsner Clinic Foundation, New Orleans, LA.
Allergists perform a range of procedures with inherent risks of anaphylaxis. This study developed risk assessments for various procedures performed at our specialized referral center based on the frequency of epinephrine use during these procedures. During a 5.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!